文献速递间质性肺疾病

纤维化间质性肺病中纵隔淋巴结动态变化与死亡及纤维化进展相关

Longitudinal Mediastinal Lymph Node Dynamics Associate With Mortality and Fibrosis Progression in Fibrotic Interstitial Lung Disease.
PubMed 文献 · Chest · 2026-07-07

本研究基于前瞻性队列(N=1122)及独立重复队列(n=181),评估纤维化间质性肺病患者纵隔淋巴结大小、数量及进展与生理下降、纤维化进展和无移植生存的关系。基线纵隔淋巴结增大(≥10 mm)占67%,与更差的无移植生存独立相关(HR 2.44,95%CI 2.01-2.96,P<.0001);纵隔淋巴结进展与超额死亡相关(校正HR 4.09,95%CI 2.34-7.17,P<.001),并修饰纤维化进展与生存的关联(交互HR 3.02,P=.001)。将纵隔淋巴结指标加入基于ILD-GAP或进行性肺纤维化状态的临床模型可适度改善风险判别。

要点

  • 基线纵隔淋巴结增大(≥10 mm)在纤维化间质性肺病中占67%,与更差无移植生存独立相关。
  • 纵隔淋巴结进展与超额死亡相关,并修饰纤维化进展与生存的关联。
  • 纵隔淋巴结指标可为现有临床模型提供补充信息并适度改善风险判别。

核心结论

  • 纵隔淋巴结负荷和进展是与纤维化间质性肺病不良结局相关的可及、可量化影像生物标志物。
  • 将纵隔淋巴结指标纳入现有临床模型可改善风险判别,支持进一步评估其在间质性肺病风险分层中的作用。

研究设计与样本

  • 前瞻性队列研究,来自三级中心的纤维化间质性肺病患者(N=1122),并设独立重复队列(n=181)。
  • 纵隔淋巴结采用标准化放射学标准评分;纤维化通过深度纹理分析量化。
  • 采用Cox和线性混合效应模型评估与结局的关联;采用Harrell一致性指数评估模型判别,决策曲线分析评估净获益。

主要发现

  • 基线纵隔淋巴结增大(≥10 mm)占67%,与更差的无移植生存独立相关(HR 2.44;95%CI 2.01-2.96;P<.0001)。
  • 纵隔淋巴结进展与超额死亡相关(校正HR 4.09;95%CI 2.34-7.17;P<.001)。
  • 纵隔淋巴结进展修饰纤维化进展与生存的关联(交互HR 3.02;P=.001)。
  • 纤维化仍是更强的预后标志物,但纵隔淋巴结指标在纤维化分层内提供补充信息,加入基于ILD-GAP模型评分或进行性肺纤维化状态的临床模型后适度改善判别。
  • 结果在独立重复队列中方向一致。

关键数值与推荐

  • 纵隔淋巴结增大定义为≥10 mm。
  • 基线纵隔淋巴结增大与无移植生存的HR为2.44(95%CI 2.01-2.96;P<.0001)。
  • 纵隔淋巴结进展与死亡的校正HR为4.09(95%CI 2.34-7.17;P<.001)。
  • 纵隔淋巴结进展与纤维化进展对生存的交互HR为3.02(P=.001)。

临床怎么用

  • 在纤维化间质性肺病评估中可关注纵隔淋巴结大小、数量及随访变化,作为风险分层的补充影像指标。
  • 纵隔淋巴结指标可加入基于ILD-GAP或进行性肺纤维化状态的临床模型以辅助风险判别。
  • 纵隔淋巴结进展可能提示超额死亡风险,需结合纤维化进展综合评估。

局限性

  • 原文未报告需注意的局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although mediastinal lymph node (MLN) enlargement is common in fibrotic interstitial lung disease (ILD), its dynamic behavior and prognostic value are unclear. RESEARCH QUESTION: Do MLN size, count, and progression on high-resolution chest CT imaging associate with physiological decline, fibrosis progression, and transplant-free survival, and do these factors improve risk models? STUDY DESIGN AND METHODS: This study included a prospective cohort of patients with fibrotic ILD from a tertiary center (N = 1,122) with independent replication (n = 181). MLNs were scored by using standardized radiologic criteria; fibrosis was quantified according to deep texture analysis. Associations with outcomes were evaluated by using Cox and linear mixed-effects models; model discrimination was assessed by using Harrell's concordance index and net benefit by decision curve analysis. RESULTS: Baseline MLN enlargement (≥ 10 mm) occurred in 67% and was independently associated with worse transplant-free survival (hazard ratio, 2.44; 95% CI, 2.01-2.96; P < .0001). MLN progression was associated with excess mortality (adjusted hazard ratio, 4.09; 95% CI, 2.34-7.17; P < .001) and modified the association between fibrosis progression and survival (interaction hazard ratio, 3.02; P = .001). Fibrosis remained the stronger prognostic marker, but MLN metrics added complementary information within fibrosis strata and modestly improved discrimination when added to clinical models based on ILD-GAP (gender, age, physiology) model score or progressive pulmonary fibrosis status. Findings were directionally consistent in the independent replication cohort. INTERPRETATION: MLN burden and progression are accessible, quantifiable imaging biomarkers associated with adverse outcomes in fibrotic ILD. Incorporating MLN metrics into existing clinical models improves risk discrimination and supports further evaluation of their role in ILD risk stratification.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Adegunsoye A, Oldham JM, Aracena KA, et al. Longitudinal Mediastinal Lymph Node Dynamics Associate With Mortality and Fibrosis Progression in Fibrotic Interstitial Lung Disease. Chest. 2026. PMID: 42413723. doi:10.1016/j.chest.2026.05.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。